Myasthenia gravis is classified as a neurology disease. Therefore, patients should visit the neurology department for medical consultation. Fundamentally, it is an immune disorder of the nervous system characterized by the production of abnormal antibodies. These antibodies affect the acetylcholine receptors on the postsynaptic membrane, thereby impacting the transmission of nerve impulses at the neuromuscular junction, which leads to various clinical symptoms. Patients may experience ptosis, double vision, and potentially compromised swallowing function, causing overall weakness. Symptoms typically worsen towards the evening. Many patients also present with thymus abnormalities. Treatment generally involves oral medications, predominantly corticosteroids and cholinesterase inhibitors.